Cytotoxic T lymphocyte-mediated immunotherapy

Details Cytotoxic T lymphocyte-mediated immunotherapy Cytotoxic T lymphocyte-mediated immunotherapy

1996-11-15

1999-10-05

Campell, Bruce R.

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

435373, 435377, 424 931, A01N 6300, C12N 500

Patent

active

059623187

ABSTRACT:
The present invention is directed to methods for stimulating primary and secondary effector cell responses for cellular immunotherapy. Cellular immunotherapy can successfully prevent or treat various viral infections and tumors, such as posttransplant EBV lymphoma. The present invention offers a general method for effecting cellular immunotherapy by providing for presentation, by the most effective antigen presenting cells, viral particles or specific antigens, without the need to develop an active viral infection in the antigen presenting cells. Furthermore, the present invention provides for generating effector cells against more than one opportunistic pathogen, e.g., Epstein-Barr virus and adenovirus. The effector cells generated according to the invention, which include CD4 and CD8 cells, are extremely long lived in vivo after adoptive transfer. In specific embodiments, dendritic cells present whole adenovirus particles via class I MHC molecules, transduced dendritic cells present a weak EBV antigen to effector cells, and EBV-transformed lymphoblastoid cells present whole adenoviral particles to effector cells, generating a population of effector cells active against EBV and adenovirus. Moreover, the adenovirus-specific effector cells of the present invention, generated against one adenovirus subgroup, recognize different adenovirus subgroups.

REFERENCES:
patent: 5405940 (1995-04-01), Boon et al.
patent: 5474935 (1995-12-01), Chatterjee et al.
I Tarpey et al (1994) Immunology 81: 222-227.
SF Macatonia (1989) J Exp Med 169: 1255-1264.
A Mehta-Damani et al (1994) J Immunology 153: 996-1003.
ABH Bakker et al (1995) Cancer Research 55: 5330-5334.
A Bender et al (1995) J Exp Med 182: 1663-1671.
A Bender et al (1996) J Immunological Methods 196: 121-135.
D Torpey et al (1993) Clinical Immunology and Immunopathology 68: 263-272.
J Lieberman et al (1995) AIDS Research and Human Retroviruses 11: 257-271.
H Koeppen et al (1993) Eur J Immunology 23: 2770-2776.
PG Coulie et al (1993) J immunotherapy 14: 104-109.
T Matsumura et al. (1993) Cancer Research 53: 4315-4321.
Chuck and Palsson, Biotech. Bioeng. 51:260-270 (1996).
Hanenberg et al., Nature Medicine 2:876 (1996).
Heslop et al., Nature Med. 2:551 (1996).
Bender et al., J. Exp. Med. 182:1663-1671 (1995).
Flomenberg et al., J. Infect. Dis. 171:1090-6 (1995).
Hill and Ploegh, Proc. Natl. Acad. Sci. USA 92:341-343 (1995).
Huang et al., J. VIrol. 69:2257-63 (1995).
Rooney et al., Lancet 345:9-13 (1995).
Smith et al., J. Hematother. 4:73-79 (1995).
Souberielle and Russell, J. Infect. Dis. 172:1421-1422 (1995).
Stevenson et al., J. Virol. 69:2850-7 (1995).
Walter et al., New Engl. J. Med., 333:1038-1044 (1995).
Yang et al., Proc. Natl. Acad. Sci. USA, 92:7257-7261 (1995).
Beier et al., J. Immunol. 304:3862-3871 (1994).
Flomenberg et al., J. Infect. Dis., 169:775-781 (1994).
Hromas et al., Blood, 84:1689-1690 (1994).
Mathias et al., J. Virol. 68:6811-14 (1994).
Romani et al., J. Exp. Med. 180:83-93 (1994).
Yang et al., Nature Genet., 7:362-369 (1994).
Berzofsky and Berkower, Fundamental Immunology, Third Edition, Paul (ed.), Raven Press, Ltd.: New York, pp. 258-259 (1993).
Wickham et al, Cell 73:309-319 (1993).
Tigges et al., J. Virol. 66:1622-1634 (1992).
Riddell et al. J. Immunol. 146:2795-2804 (1991).
Wold and Gooding, Virology, 184:1-8 (1991).
Defer et al., J. Virol. 64:3661-73 (1990).
Gooding and Wold, Crit. Rev. Immunol., 10:53-71 (1990).
Rooney et al., Lancet, 345:9-12 (1990).
Romani et al., J. Exp. Med. 169:1169-1174 (1989).

Affiliated with

Also associated with

Rating

Cytotoxic T lymphocyte-mediated immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cytotoxic T lymphocyte-mediated immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic T lymphocyte-mediated immunotherapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1170800